Brendan specializes in structuring and negotiating strategic, complex “bet-the-company” collaborations, licenses, joint ventures and carve-out transactions on behalf of private and public companies in the biotechnology, pharmaceutical, medical device, agritech, and genomics industries. His experience also includes counseling clients in connection with pre-clinical and clinical research agreements, supply agreements, manufacturing agreements, and distribution agreements. In addition to representing company clients in their partnering and licensing activities, Brendan also represents a number of prominent venture capital funds and institutional investors in their financing activities and in their incubation and formation of life science companies.

Brendan has negotiated numerous licensing arrangements opposite major research institutions, particularly in situations where venture capital investors or entrepreneurs are licensing foundational intellectual property for a new biotechnology company. His representative experience in this regard includes negotiating such agreements opposite the following research institutions (among various others): Broad Institute, CalTech, Cornell University, Dana-Farber Cancer Institute, Duke University, Fred Hutchinson Cancer Research Center, Harvard University, MD Anderson, MIT, Moffitt Cancer Center, Stanford University, University of California (various campuses), University of Cambridge, University of Oxford, University of Michigan, University of Texas (various campuses), University of Washington, and Yale University.

Prior to joining Gunderson Dettmer, Brendan was an attorney in the Palo Alto office of Cooley LLP.

Brendan holds a J.D. from the University of Chicago Law School as well as a B.S., with honors, in Computer Engineering from the University of Illinois at Urbana-Champaign. Brendan is a member of the State Bar of California.